Table 1.
Distribution of telavancin MIC values obtained using rBMD on HAP isolates from ATTAIN trials
| Organism | Method | MIC (µg/mL) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N | 0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1.0 | Range (µg/mL) | MIC50/90 (µg/mL) | ||
| S. aureus (all) | Revised | 647 | 3 | 167 | 413 | 64a | – | – | – | 0.015–0.12 | 0.06/0.06 |
| Original | 644 | – | – | 2 | 13 | 346 | 258 | 25 | 0.06–1 | 0.25/0.50 | |
| MSSA | Revised | 240 | 1 | 94 | 144 | 1 | – | – | – | 0.015–0.12 | 0.06/0.06 |
| Original | 239 | – | – | – | 10 | 178 | 50 | 1 | 0.12–1 | 0.25/0.5 | |
| MRSA | Revised | 407 | 2 | 73 | 269 | 63 | – | – | 0.015–0.12 | 0.06/0.12 | |
| Original | 405 | – | – | 2 | 3 | 168 | 208 | 24 | 0.06–1 | 0.5/0.5 | |
| S. aureus vancomycin MIC ≥1 µg/mL | Revised | 528 | – | 94 | 370 | 61 | 3a | – | – | 0.03–0.25 | 0.06/0.12 |
| Original | 466 | – | – | – | 7 | 229 | 209 | 21 | 0.12–1 | 0.25/0.5 | |
| MSSA vancomycin MIC ≥1 µg/mL | Revised | 166 | – | 48 | 117 | 1 | – | – | – | 0.03–0.12 | 0.06/0.06 |
| Original | 137 | – | – | – | 5 | 103 | 29 | – | 0.12–0.5 | 0.25/0.5 | |
| MRSA vancomycin MIC ≥1 µg/mL | Revised | 362 | – | 46 | 253 | 60 | 3 | – | – | 0.03–0.25 | 0.06/0.12 |
| Original | 329 | – | – | – | 2 | 126 | 180 | 21 | 0.12–1 | 0.5/0.5 | |
Data presented as number of isolates except where indicated
ATTAIN Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia; HAP hospital-acquired pneumonia; MIC minimum inhibitory concentration; MRSA methicillin-resistant S. aureus; MSSA methicillin-susceptible S. aureus; rBMD revised broth microdilution; S. aureus Staphylococcus aureus